Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
NEXALIN TECHNOLOGY INC (NXL)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-05
$1.40-10.26%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-05
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for NXL yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Completion of pivotal clinical trial for HALO Clarity | The company is advancing a pivotal clinical trial and formed a key partnership with GreenLight Ventures. | Intact | trial delays or negative results reported | Qualitative condition This condition has no defined numerical measure. Nov 5, 2026Last status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk, speculative growth story rather than an established, profitable business. Its long-term thesis depends on turning a new South American agreement into meaningful commercial activity, while the current thesis remains on watch.
The valuation evidence points to an expensive position versus peers, with a sizable expectations gap tied to future potential. Model confidence is low, and the evidence says the valuation is expensive without the broader combination of weakness and turbulence that would make priced-in fragility high.
Near term, ongoing operating losses, declining revenue, consecutive earnings misses, and the need for new funding leave execution uncertain. The 10-year South American distribution and manufacturing agreement is a strategic shift, but its revenue impact is still early and limited. Healthcare sector momentum has strengthened, though weaker jobs data and bellwether results could affect the near-term backdrop.
Over the multi-year view, the central question is whether the South American agreement creates enough commercial revenue to improve the business while losses continue. Near term, weakening employment data could increase pressure on cyclical healthcare names, while continued strong results from ABT, MDT, and SYK could sustain sector support. Listing compliance and access to financing also remain important swing factors.
For the next 1 to 3 years, NXL remains a watch-stage, high-risk thesis with early commercial potential but limited proof of financial progress. The outcome hinges on execution, funding, and whether the sector backdrop stays supportive. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| The new CFO may stabilize management and execution. |
| Under Pressure |
| continued management volatility or execution failures |
Qualitative: SVP departure + Nasdaq delisting notice SVP Carolyn Shelton departed; Nasdaq issued delisting notice; earnings missed estimates. Nov 5, 2026Last status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Resolution of Nasdaq listing deficiency | A supporting condition in NEXALIN TECHNOLOGY INC's published investment case. The stated target is Nasdaq deficiency resolved. | Under Pressure | delisting or failure to resolve deficiency | Delisting notice issued vs resolution target Nasdaq issued a Notice of Delisting on 2026-09-28 following the company's compliance plan presentation. Nov 5, 2026Last status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in a supplied disclosure. Management reported: “Exhibit 99.1 Nexalin Technology Announces Reverse Stock Split HOUSTON – August 27, 2026 – Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), announces that its board of directors has approved a 1-for-30 reverse stock split of the Company’s common stock, to ensure continued compliance with the Nasdaq bid-price rule.” Delivery assessment Nov 5, 2026 |
Revenue growth to $690K in FY27 | A primary condition in NEXALIN TECHNOLOGY INC's published investment case. The stated target is >= $690,000 in revenue. | Broken | revenue falls below $345,000 in FY26 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.31 → $-7.55 · observed estimates
$0.00B → $0.00B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.31 | $690,000 | 1 / 1 |
| 2026-07-25 | $-0.31 | $690,000 | 1 / 1 |
| 2026-07-26 | $-0.31 | $690,000 | 1 / 1 |
| 2026-07-27 | $-0.31 | $690,000 | 1 / 1 |
| 2026-07-28 | $-0.31 | $690,000 | 1 / 1 |
| 2026-07-29 | $-0.31 | $690,000 | 1 / 1 |
| 2026-07-30 | $-0.31 | $690,000 | 1 / 1 |
| 2026-07-31 | $-0.31 | $690,000 | 1 / 1 |
| 2026-08-01 | $-0.31 | $690,000 | 1 / 1 |
| 2026-08-02 | $-0.31 | $690,000 | 1 / 1 |
| 2026-08-03 | $-0.31 | $690,000 | 1 / 1 |
| 2026-08-04 | $-0.31 | $690,000 | 1 / 1 |
| 2026-08-05 | $-0.31 | $690,000 | 1 / 1 |
| 2026-08-06 | $-0.31 | $690,000 | 1 / 1 |
| 2026-08-07 | $-0.31 | $690,000 | 1 / 1 |
| 2026-08-08 | $-0.31 | $690,000 | 1 / 1 |
| 2026-08-09 | $-0.31 | $690,000 | 1 / 1 |
| 2026-08-10 | $-0.31 | $690,000 | 1 / 1 |
| 2026-08-12 | $-0.31 | $690,000 | 1 / 1 |
| 2026-08-13 | $-0.31 | $690,000 | 1 / 1 |
| 2026-08-14 | $-0.31 | $690,000 | 1 / 1 |
| 2026-08-15 | $-0.31 | $690,000 | 1 / 1 |
| 2026-08-16 | $-0.31 | $690,000 | 1 / 1 |
| 2026-08-17 | $-0.31 | $690,000 | 1 / 1 |
| 2026-08-18 | $-0.31 | $690,000 | 1 / 1 |
| 2026-08-19 | $-0.31 | $690,000 | 1 / 1 |
| 2026-08-20 | $-0.31 | $690,000 | 1 / 1 |
| 2026-08-21 | $-0.31 | $690,000 | 1 / 1 |
| 2026-08-22 | $-0.31 | $690,000 | 1 / 1 |
| 2026-08-23 | $-0.31 | $690,000 | 1 / 1 |
| 2026-08-24 | $-0.31 | $690,000 | 1 / 1 |
| 2026-08-25 | $-0.31 | $690,000 | 1 / 1 |
| 2026-08-26 | $-0.31 | $690,000 | 1 / 1 |
| 2026-08-27 | $-0.31 | $690,000 | 1 / 1 |
| 2026-08-28 | $-0.31 | $690,000 | 1 / 1 |
| 2026-08-29 | $-0.31 | $690,000 | 1 / 1 |
| 2026-08-30 | $-0.31 | $690,000 | 1 / 1 |
| 2026-08-31 | $-0.31 | $690,000 | 1 / 1 |
| 2026-09-01 | $-9.30 | $690,000 | 1 / 1 |
| 2026-09-02 | $-9.30 | $690,000 | 1 / 1 |
| 2026-09-03 | $-9.30 | $690,000 | 1 / 1 |
| 2026-09-04 | $-9.30 | $690,000 | 1 / 1 |
| 2026-09-05 | $-9.30 | $690,000 | 1 / 1 |
| 2026-09-06 | $-9.30 | $690,000 | 1 / 1 |
| 2026-09-07 | $-9.30 | $690,000 | 1 / 1 |
| 2026-09-08 | $-9.30 | $690,000 | 1 / 1 |
| 2026-09-09 | $-9.30 | $690,000 | 1 / 1 |
| 2026-09-10 | $-9.30 | $690,000 | 1 / 1 |
| 2026-09-11 | $-9.30 | $690,000 | 1 / 1 |
| 2026-09-12 | $-9.30 | $690,000 | 1 / 1 |
| 2026-09-13 | $-9.30 | $690,000 | 1 / 1 |
| 2026-09-14 | $-9.30 | $690,000 | 1 / 1 |
| 2026-09-15 | $-9.30 | $690,000 | 1 / 1 |
| 2026-09-16 | $-9.30 | $690,000 | 1 / 1 |
| 2026-09-17 | $-9.30 | $690,000 | 1 / 1 |
| 2026-09-18 | $-9.30 | $690,000 | 1 / 1 |
| 2026-09-19 | $-9.30 | $690,000 | 1 / 1 |
| 2026-09-20 | $-9.30 | $690,000 | 1 / 1 |
| 2026-09-21 | $-9.30 | $690,000 | 1 / 1 |
| 2026-09-22 | $-9.30 | $690,000 | 1 / 1 |
| 2026-09-23 | $-9.30 | $690,000 | 1 / 1 |
| 2026-09-24 | $-9.30 | $690,000 | 1 / 1 |
| 2026-09-25 | $-9.30 | $690,000 | 1 / 1 |
| 2026-09-26 | $-9.30 | $690,000 | 1 / 1 |
| 2026-09-27 | $-9.30 | $690,000 | 1 / 1 |
| 2026-09-28 | $-9.30 | $690,000 | 1 / 1 |
| 2026-09-29 | $-9.30 | $690,000 | 1 / 1 |
| 2026-09-30 | $-9.30 | $690,000 | 1 / 1 |
| 2026-10-01 | $-9.30 | $690,000 | 1 / 1 |
| 2026-10-02 | $-7.55 | $337,500 | 1 / 1 |
| 2026-10-03 | $-7.55 | $337,500 | 1 / 1 |
| 2026-10-04 | $-7.55 | $338,000 | 1 / 1 |
| 2026-10-05 | $-7.55 | $338,000 | 1 / 1 |
| 2026-10-06 | $-7.55 | $338,000 | 1 / 1 |
| 2026-10-07 | $-7.55 | $338,000 | 1 / 1 |
| 2026-10-08 | $-7.55 | $338,000 | 1 / 1 |
| 2026-10-09 | $-7.55 | $338,000 | 1 / 1 |
| 2026-10-10 | $-7.55 | $338,000 | 1 / 1 |
| 2026-10-11 | $-7.55 | $338,000 | 1 / 1 |
| 2026-10-12 | $-7.55 | $338,000 | 1 / 1 |
| 2026-10-13 | $-7.55 | $338,000 | 1 / 1 |
| 2026-10-14 | $-7.55 | $338,000 | 1 / 1 |
| 2026-10-15 | $-7.55 | $338,000 | 1 / 1 |
| 2026-10-16 | $-7.55 | $338,000 | 1 / 1 |
| 2026-10-17 | $-7.55 | $338,000 | 1 / 1 |
| 2026-10-18 | $-7.55 | $338,000 | 1 / 1 |
| 2026-10-19 | $-7.55 | $338,000 | 1 / 1 |
| 2026-10-20 | $-7.55 | $338,000 | 1 / 1 |
| 2026-10-21 | $-7.55 | $338,000 | 1 / 1 |
| 2026-10-22 | $-7.55 | $338,000 | 1 / 1 |
| 2026-10-23 | $-7.55 | $338,000 | 1 / 1 |
| 2026-10-24 | $-7.55 | $338,000 | 1 / 1 |
| 2026-10-25 | $-7.55 | $338,000 | 1 / 1 |
| 2026-10-26 | $-7.55 | $338,000 | 1 / 1 |
| 2026-10-27 | $-7.55 | $338,000 | 1 / 1 |
| 2026-10-28 | $-7.55 | $338,000 | 1 / 1 |
| 2026-10-29 | $-7.55 | $338,000 | 1 / 1 |
| 2026-10-30 | $-7.55 | $338,000 | 1 / 1 |
| 2026-10-31 | $-7.55 | $338,000 | 1 / 1 |
| 2026-11-01 | $-7.55 | $338,000 | 1 / 1 |
| 2026-11-02 | $-7.55 | $338,000 | 1 / 1 |
| 2026-11-03 | $-7.55 | $338,000 | 1 / 1 |
| 2026-11-04 | $-7.55 | $338,000 | 1 / 1 |
| 2026-11-05 | $-7.55 | $338,000 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 1 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 7–Nov 5 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 7, 2026–Nov 5, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Nov 13, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.